Eloxx Pharmaceuticals, Inc. ELOX
Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX) is a rare genetic drug developer. Its lead program, exaluren, is in Phase 2 for Alport syndrome with nonsense mutations (NMAS). Its next catalyst on record is exaluren: First patient dosing in EXPRESS Phase 2 trial of exaluren in ADPKD expected in third quarter 2027. (Q3 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: exaluren — First patient dosing in EXPRESS Phase 2 trial of exaluren in ADPKD expected in third quarter 2027. (Q3 2027). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| exaluren | Alport syndrome with nonsense mutations (NMAS), Phase 2b cleared and planned | small molecule | Phase 2 |
| exaluren | nonsense-mutation autosomal dominant polycystic kidney disease (nmADPKD) | small molecule | Pre-clinical |
| ZKN-013 (licensed to Almirall) | RDEB and JEB with nonsense mutations | small molecule | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 rare genetic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.